German multinational Boehringer Ingelheim is opening a new production plant in Sant Cugat, Spain for which the first stone was placed by Jordi Baiget, Minister for Business and Knowledge. The new production plant will cost about 100 million euros ($118.38 million) and will create 200 new jobs. Boehringer Ingelheim’s new plant will produce a drug delivery device named Respimat, a device that will contain different types of inhalers to treat illnesses such as COPD or asthma. With the support of Catalan Government, Catalonia Trade & Investment and ACCIO’s area for foreign investment attraction, Boehringer Ingelheim chose Sant Cugat over other locations in Europe.
Set to produce 25 million units per year and with the fully operational capacity of 30 million, Boehringer Ingelheim will distribute the medicine in Europe, Japan, United States, Mexico, Canada and Brazil.
About Boehringer Ingelheim
Established in 1952, Boehringer Ingelheim is a pharmaceutical company that was founded in 1885 and is headquartered in Ingelheim in Germany. It employs around 1,700 workers in the facilities of Sant Cugat del Vallès and Malgrat de Mar while it employs around 50,000 workers worldwide. One of the pharmaceutical industry’s top 20 companies, Boehringer Ingelheim achieved net sales of around 15.9 billion euros ($18.8 billion) while still remaining a family owned company.